The clinical impact and outcomes of immunohistochemistry-only metastasis in breast cancer - 19/08/11
Abstract |
Background |
Modern surgical and pathological techniques can detect small-volume axillary metastases in breast cancer with unknown clinical significance.
Methods |
A retrospective database review from 1996 through 2004 identified all patients with immunohistochemical (IHC)-only sentinel node (IHC-SN) metastases and compared them with negative controls (Neg-SN).
Results |
When comparing the 232 IHC-SN patients with the 252 Neg-SN controls, the IHC-SN patients had larger tumors, more lobular histology, a higher grade, and more HER2/neu positivity. They also received more systemic therapy. With a median follow-up of 5 years, there were no differences in recurrence-free survival or overall survival. In 123 IHC-SN patients treated with axillary dissection (axillary lymph node dissection), 16% had positive non-SLNs. Patients with positive non-SLNs tended to have worse outcomes.
Conclusions |
IHC-only sentinel lymph node (SLN) metastases were associated with worse prognostic features and higher rates of systemic therapy. However, no outcomes differences were noted.
Le texte complet de cet article est disponible en PDF.Keywords : Breast cancer, Sentinel lymph node biopsy, Sentinel lymph node, Isolated tumor cells, Micrometastasis, Nanometastasis, Immunohistochemical-only sentinel lymph node, Immunohistochemical N0(I+)
Plan
Vol 200 - N° 3
P. 368-373 - septembre 2010 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?